多参数磁共振系统漏诊何种前列腺癌?PROMIS队列分析
基于PROMIS队列,以5mm模板穿刺为参考标准,评估mpMRI漏诊前列腺癌的特征。mpMRI漏诊显著癌的比例为7%(定义1)至13%(定义2),远低于TRUS活检的52%和40%。漏诊癌的Gleason评分更低、最大癌芯长度更短,且无总体Gleason>3+4或最高Gleason>4+3的肿瘤被漏诊。
要点
- mpMRI漏诊显著癌比例低(定义1为7%,定义2为13%),远优于TRUS活检。
- 漏诊癌的Gleason评分和最大癌芯长度显著低于检出癌。
- 无总体Gleason>3+4或最高Gleason>4+3的肿瘤被mpMRI漏诊。
核心结论
- mpMRI漏诊的总体癌比例较小,估计范围从4.4%(定义1的95%CI下限)到17%(定义2的95%CI上限)。
- mpMRI未检出的前列腺癌比检出的癌症分级更低、长度更短。
- 无最高侵袭性癌被mpMRI漏诊。
研究设计与样本
- PROMIS研究评估mpMRI和TRUS引导活检的性能,以5mm模板映射(TPM)活检为参考标准。
- 分析纳入有癌症的男性,比较mpMRI漏诊与检出癌症的属性。
主要发现
- mpMRI漏诊显著癌:定义1为7%(17/230;95%CI 4.4-12%),定义2为13%(44/331;95%CI 9.8-17%)。
- TRUS活检漏诊显著癌:定义1为52%(119/230;95%CI 45-58%),定义2为40%(132/331;95%CI 35-45%)。
- mpMRI未检出癌的总体和最高Gleason评分显著更低(p=0.0007;p<0.0001),最大癌芯长度更短(中位差3mm [5 vs 8 mm],p<0.0001;95%CI 1-3)。
- 无TPM活检总体Gleason>3+4(Gleason分级组3-5;95%CI 0-6.4%)或最高Gleason>4+3(Gleason分级组4-5;95%CI 0-8.0%)的肿瘤被mpMRI漏诊。
- 应用PSAD阈值0.15,定义1漏诊比例降至5%(12/230;95%CI 2.7-8.9%),定义2降至9%(30/331;95%CI 6.2-13%)。
关键数值与推荐
- 显著癌定义1:Gleason≥4+3任意长度或MCCL≥6mm任意分级。
- 显著癌定义2:Gleason≥3+4任意长度或MCCL≥4mm。
- PSAD阈值0.15和0.10可降低mpMRI漏诊比例。
临床怎么用
- mpMRI对显著前列腺癌的漏诊率低,尤其高级别癌,支持其用于风险分层。
- 结合PSAD阈值(如0.15或0.10)可进一步减少漏诊。
- 对于mpMRI阴性但PSAD较高者,仍需考虑活检。
局限性
- 事后分析。
- 未检出病变的临床意义不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: All risk stratification strategies in cancer overlook a spectrum of disease. The Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore cancers that are overlooked by multiparametric magnetic resonance imaging (mpMRI). OBJECTIVE: To summarise attributes of cancers that are systematically overlooked by mpMRI. DESIGN, SETTING, AND PARTICIPANTS: PROMIS tested performance of mpMRI and transrectal ultrasonography (TRUS)-guided biopsy, using 5 mm template mapping (TPM) biopsy as the reference standard. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were overall and maximum Gleason scores, maximum cancer core length (MCCL), and prostate-specific antigen density (PSAD). Cancer attributes were compared between cancers that were overlooked and those that were detected. RESULTS AND LIMITATIONS: Of men with cancer, 7% (17/230; 95% confidence interval [CI] 4.4-12%) had significant disease overlooked by mpMRI according to definition 1 (Gleason ≥ 4 + 3 of any length or MCCL ≥ 6 mm of any grade) and 13% (44/331; 95% CI 9.8-17%) according to definition 2 (Gleason ≥ 3 + 4 of any length or MCCL ≥ 4 mm). In comparison, TRUS-guided biopsy overlooked 52% (119/230; 95% CI 45-58%) of significant disease by definition 1 and 40% (132/331; 95% CI 35-45%) by definition 2. Prostate cancers undetected by mpMRI had significantly lower overall and maximum Gleason scores (p = 0.0007; p < 0.0001) and shorter MCCL (median difference: 3 mm [5 vs 8 mm], p < 0.0001; 95% CI 1-3) than cancers that were detected. No tumours with overall Gleason score > 3 + 4 (Gleason Grade Groups 3-5; 95% CI 0-6.4%) or maximum Gleason score > 4 + 3 (Gleason Grade Groups 4-5; 95% CI 0-8.0%) on TPM biopsy were undetected by mpMRI. Application of a PSAD threshold of 0.15 reduced the proportion of men with undetected cancer to 5% (12/230; 95% CI 2.7-8.9%) for definition 1 and 9% (30/331; 95% CI 6.2-13%) for definition 2. Application of a PSAD threshold of 0.10 reduced the proportion of men with undetected disease to 3% (6/230; 95% CI 1.0-5.6%) for definition 1 cancer and to 3% (11/331; 95% CI 1.7-5.9%) for definition 2 cancer. Limitations were post hoc analysis and uncertain significance of undetected lesions. CONCLUSIONS: Overall, a small proportion of cancers are overlooked by mpMRI, with estimates ranging from 4.4% (lower boundary of 95% CI for definition 1) to 17% (upper boundary of 95% CI for definition 2). Prostate cancers undetected by mpMRI are of lower grade and shorter length than cancers that are detected. PATIENT SUMMARY: Prostate cancers that are undetected by magnetic resonance imaging (MRI) are smaller and less aggressive than those that are detected, and none of the most aggressive cancers are overlooked by MRI.
引用
- Norris JM, Carmona Echeverria LM, Bott SRJ, et al. What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. Eur Urol. 2020. PMID: 32370911. doi:10.1016/j.eururo.2020.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。